Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02811497
Title Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

Her2-receptor negative breast cancer

ovary epithelial cancer

colorectal cancer

Advanced Solid Tumor

Therapies

Azacitidine + Durvalumab

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.